-
A Phase 2a Multicenter Dose Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a Phase 2 study testing a treatment called SYNC-T Therapy SV-102 in adult men with metastatic castration-resistant prostate cancer (mCRPC). SYNC-T Therapy SV-102 ...
Phase
Interventional
-
A Phase 3 Randomized Open-label Study of Pasritamig (JNJ-78278343) a T-cell-redirecting Agent Targeting Human Kallikrein 2 With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate CancerPhase
Interventional
-
A PHASE 1 OPEN-LABEL MULTICENTER STUDY OF JANX007 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
This study is a first-in-human (FIH), Phase 1, open-label, multicenter study to assess the safety, tolerability, PK, PD, and preliminary efficacy of JANX007 administered as ...Phase
Interventional
-
A PHASE II PROSPECTIVE TRIAL UTILIZING SHORT COURSE ANDROGEN DEPRIVATION THERAPY IN CONJUNCTION WITH ULTRA-HYPOFRACTIONATED SBRT FOR HIGH RISK NCCN PROSTATE CANCER WITH LOWER RISK ARTERA SCORES
This is a Phase 2 study for patients with high-risk prostate cancer who have Gleason scores of 8–10 or PSA levels between 20 and ...
Phase
Interventional
